DRUG UTILIZATION STUDIES AS TOOLS IN HEALTH ECONOMICS

被引:18
作者
SACRISTAN, JA
SOTO, J
机构
[1] Health Economics Department, Clinical Research Department, Lilly S.A., Madrid, Avenida de la Industria, 30
[2] Pharmacoepiderniology Department, Abbott Laboratories, Madrid
关键词
D O I
10.2165/00019053-199405040-00005
中图分类号
F [经济];
学科分类号
02 ;
摘要
Drug utilisation and many pharmacoeconomic studies use pharmacoepidemiological methods characterised by the study of drugs from a socioeconomic perspective. Drug utilisation studies may be defined as studies of the marketing, distribution, prescription and use of drugs in a society, with special emphasis on the resulting medical, social and economic consequences. Pharmacoeconomic studies are used to measure drug efficiency, through comparison of the costs and effects of alternative therapies. Drug utilisation studies can provide highly valuable information, at a reasonable price, on the costs and effects (harmful and beneficial) of drugs. Such studies make available much useful information including indirect data on morbidity, the pharmaceutical component of the treatment cost of an illness, therapeutic compliance, the incidence of adverse reactions, the effectiveness of drug consumption and the choice of comparators. This information can be of great use in the subsequent elaboration of pharmacoeconomic studies, or in the selection of problematic areas in which these studies may be applied. Pharmacoeconomic studies, in turn, can be used to discover the economic repercussions of inappropriate prescribing and to quantify the cost effectiveness of various therapeutic interventions. The use of drug utilisation studies in conjunction with pharmacoeconomic analysis can result in more cost effective utilisation of medicines and a better utilisation of pharmacoeconomic methods, both of which contribute to a more rational use of drugs.
引用
收藏
页码:299 / 312
页数:14
相关论文
共 79 条
[1]  
Agenas I., Andrew M., Sales statistics, In Nordic Statistics on Medicines 1981-1983: 1, NLN Publication number 13, (1983)
[2]  
Avorn J., Soumerai S.B., Improving drug-therapy decision through educational outreach: a randomized controlled trial of academically based ‘detailing’, New England Journal of Medicine, 308, pp. 1457-1463, (1983)
[3]  
Baksaas I., Patterns in drug utilization: national and international aspects - antihypertensive drugs, Acta Medica Scandinavica, 683, pp. 59-66, (1984)
[4]  
Baksaas I., Ltinde P.K.M., Drug utilization: pharmacokinetics in the community, Trends in Pharmacological Sciences, 2, pp. 5-7, (1981)
[5]  
Bergman U., Boman G., Wiholm B.E., Epidemiology of adverse reactions to phenformin and metformin, British Medical journal, 2, pp. 464-466, (1978)
[6]  
Bergman U., Elmes P., Halse M., Et al., The measurement of drug consumption: drugs for diabetes in Northern Ireland. Norway and Sweden, European Journal of Clinical Pharmacology, 8, pp. 33-89, (1975)
[7]  
Bergman U., Sjoqvist F., Measurement of drug utilization in Sweden: methodological and clinical implications, Acta Medica Scandinavica, 683, pp. 15-22, (1984)
[8]  
Bergman U., Wessling A., Sjoqvist F., Validation of observed differences in the utilization of antihypertensive drugs and antidiabetic drugs in Northern Ireland, Norway, and Sweden, European Journal of Clinical Pharmacology, 29, pp. 1-8, (1985)
[9]  
Blackburn J.L., Impact of drug usage review on drug utilisation, Pharmacoeconomics, 3, pp. 14-21, (1993)
[10]  
Boethius G., Approaches to assessing the rationality of drug usage in a developed country, Acta Medica Scandinavica, 721, pp. 21-26, (1988)